Peanut Allergy 50% - 62% of Fatal Food Anaphylaxis [Allergy Leading to Death] 1.5 Million Americans are Victims of Peanut Allergy

Recombinant Molecules for a Healthy Life Ida Iris Icy D’Silva WBT 2011 Innovation Marketplace Arlington, Texas, USA March 22-23, 2011 Guelph, Ontario N1G 2W1 CANADA Booth # 119

Educational Medical Industrial Agricultural Controlled Creation of Molecules through the Transfer of DNA from One Organism to Another Social Economic Social Economic Food Environmental Booth # 119 Insulin Recombinant Technology

Recombinant Molecules against Peanut Allergy Market Opportunity   Untapped [1.5 Million American Peanut Allergy Patients]   EpiPen ® [Two EpiPen ® / Year at ~US $ 100 / EpiPen ® for 75 Years = ~US $ 15,000] Benefits   Cost-Effective and Safe [~US $ 3000 and Injectionless] Booth # 119

Recombinant Molecules against Peanut Allergy Prototype Recombinant Ovalbumin Molecules Recombinant Molecule Allergy Immunity Immunotherapy Filing Patents Booth # 119

Recombinant Molecules against Peanut Allergy Business Model   Design and Development   Preclinical Studies   Clinical Trials → Phase II Revenue Model   Capital for 7 Years   Partnerships Booth # 119

Management and Organization Ida Iris Icy D’Silva PhD Graduate, University of Guelph Recombinant Technology Professor J. Christopher Hall NSERC Canada Research Chair, University of Guelph Recombinant Antibody Technology To be Added as Needed by the Company Chief Executive Officer Business Development Officer Finance Officer Staff Booth # 119

Financial Information YearFinance (US $)Usage ~2,000,000Design and Development ~10,000,000Preclinical Studies 5 - 7~15,000,000Clinical Trials → Phase II Partnerships Sought   Manufacturing, Marketing, Distribution etc. Booth # 119

Opportunity for the Investor What’s in it for the Investor?   Novel Technology   Strong Patent Potential   Cost-Effectiveness   Relatively Short Term Exit Strategy Exit Strategy   Partnerships followed by Acquisition Booth # 119